The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys
...
tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more
Kenya in undergoing an epidemiological transition marked by a decline in morbidity and mortality due to communicable conditions, and an increase in the burden of non-communicable diseases (NCDs), which include diseases such as diabetes, cancers, cardiovascular diseases and chronic respiratory infect
...
ions. The second strategic objective of KHSSP 2014-2018 targets to halt and reverse the rising burden of non-communicable conditions, while the fifth strategic objective is focused on putting into place health promotion interventions that will address risk factors to health.
more
Bulletin of the World Health Organization Volume 91, Number 4, April 2013, 237-312
UNICEF’s support for data collection: the Multiple Indicator Cluster Surveys (MICS)
Statistical Report No 25: 2014
Statistical Report | No. 39: 2013
This interagency report provides recommendations for assuring quality of medicines during key activities of country-level procurement agencies, namely prequalification of pharmaceutical products and manufacturers; purchase of pharmaceutical products; storage of pharmaceutical products; and distribut
...
ion of pharmaceutical products.
more
Le succès de la mise en œuvre du PNAPF 2017-2020 dépendra de l’engagement de chaque entité à tous les niveaux à travers des arrangements institutionnels clairs. Il s’agit d’un document dynamique qui requerra une forte coordination des différentes parties prenantes multisectorielles. La
...
mise en œuvre sera conduite par le Ministère de la Santé à travers la Direction de la Santé de la Famille (DSF). Les autres secteurs tels que les ministères connexes contribueront à favoriser l’environnement juridique et politique de la PF pour garantir l’accès de tous, notamment des jeunes aux services de PF. Les organisations de la société civile (OSC) et les PTF apporteront leur contribution à la mise en œuvre du plan, au renforcement des
capacités des acteurs en PF, au plaidoyer et à la mobilisation des ressources pour la pérennité du programme.
more
Antimicrobial resistance is one of the most important threats to the health worldwide. Antimicrobial resistance or drug resistance is the reduction of the pharmaceutical effects of a drug against a disease or reduction of its effectiveness in improving the clinical signs of a disease. Antimicrobial
...
resistance occurs naturally but misuse of antibiotics in human and animals significantly accelerates the process of developing antimicrobial resistance. In fact, antimicrobial resistance refers to the resistance of a microorganism to one or more antimicrobial drugs which had been previously sensitive to these drugs. Antimicrobial resistance can occur in a wide variety of pathogens including bacteria, parasites, viruses, fungi, and cancer cells and may threaten the life of every person, in every age, and in every country
more
TEP UP Technical Working Paper